Advanced

Effect of autoimmune diseases on mortality and survival in subsequent digestive tract cancers

Hemminki, Kari LU ; Liu, Xiangdong LU ; Ji, Jianguang LU ; Sundquist, Jan LU and Sundquist, Kristina LU (2012) In Annals of Oncology 23(8). p.2179-2184
Abstract
Patients with some autoimmune diseases (AIDs) are at increased risk of cancer, possibly a result of an underlying dysregulation of the immune system, medication, treatment or, probably, surveillance bias. Data on cancer mortality and survival in patients previously diagnosed with AIDs would provide novel information on these comorbidities and their clinical implications. Standardized mortality ratios (SMRs) and hazard ratios (HRs) were calculated for subsequent deaths from seven digestive tract cancers between 1964 and 2008 in patients hospitalized for any of 33 AIDs. There were 33 increased SMRs for specific cancers after a defined AID; similarly, 21 HRs were increased. Both the SMR and HR were increased after 10 autoimmune disorders,... (More)
Patients with some autoimmune diseases (AIDs) are at increased risk of cancer, possibly a result of an underlying dysregulation of the immune system, medication, treatment or, probably, surveillance bias. Data on cancer mortality and survival in patients previously diagnosed with AIDs would provide novel information on these comorbidities and their clinical implications. Standardized mortality ratios (SMRs) and hazard ratios (HRs) were calculated for subsequent deaths from seven digestive tract cancers between 1964 and 2008 in patients hospitalized for any of 33 AIDs. There were 33 increased SMRs for specific cancers after a defined AID; similarly, 21 HRs were increased. Both the SMR and HR were increased after 10 autoimmune disorders, including pernicious anemia, systemic lupus erythematosus and psoriasis. Increased SMRs and unchanged HRs were noted for 23 cancers. Myasthenia gravis was associated with SMRs for five cancers but no increases in HRs. For nine cancers, including esophageal cancer after ulcerative colitis and rheumatoid arthritis, the SMR was unchanged but the HR increased. The increases in SMRs provide evidence that cancer risks were truly increased and largely unaffected by surveillance bias. The prognostic survival data should contribute to clinical evaluation and therapeutic planning. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cancer mortality, immunosuppression, immune disease, medication, survival
in
Annals of Oncology
volume
23
issue
8
pages
2179 - 2184
publisher
Oxford University Press
external identifiers
  • wos:000306924400040
  • scopus:84864931877
ISSN
1569-8041
DOI
10.1093/annonc/mdr590
language
English
LU publication?
yes
id
5b6f0665-7e83-495c-a1d8-61543deb2952 (old id 3070163)
date added to LUP
2012-10-05 07:11:05
date last changed
2017-07-02 03:53:42
@article{5b6f0665-7e83-495c-a1d8-61543deb2952,
  abstract     = {Patients with some autoimmune diseases (AIDs) are at increased risk of cancer, possibly a result of an underlying dysregulation of the immune system, medication, treatment or, probably, surveillance bias. Data on cancer mortality and survival in patients previously diagnosed with AIDs would provide novel information on these comorbidities and their clinical implications. Standardized mortality ratios (SMRs) and hazard ratios (HRs) were calculated for subsequent deaths from seven digestive tract cancers between 1964 and 2008 in patients hospitalized for any of 33 AIDs. There were 33 increased SMRs for specific cancers after a defined AID; similarly, 21 HRs were increased. Both the SMR and HR were increased after 10 autoimmune disorders, including pernicious anemia, systemic lupus erythematosus and psoriasis. Increased SMRs and unchanged HRs were noted for 23 cancers. Myasthenia gravis was associated with SMRs for five cancers but no increases in HRs. For nine cancers, including esophageal cancer after ulcerative colitis and rheumatoid arthritis, the SMR was unchanged but the HR increased. The increases in SMRs provide evidence that cancer risks were truly increased and largely unaffected by surveillance bias. The prognostic survival data should contribute to clinical evaluation and therapeutic planning.},
  author       = {Hemminki, Kari and Liu, Xiangdong and Ji, Jianguang and Sundquist, Jan and Sundquist, Kristina},
  issn         = {1569-8041},
  keyword      = {cancer mortality,immunosuppression,immune disease,medication,survival},
  language     = {eng},
  number       = {8},
  pages        = {2179--2184},
  publisher    = {Oxford University Press},
  series       = {Annals of Oncology},
  title        = {Effect of autoimmune diseases on mortality and survival in subsequent digestive tract cancers},
  url          = {http://dx.doi.org/10.1093/annonc/mdr590},
  volume       = {23},
  year         = {2012},
}